A Phase 1 Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Latest Information Update: 15 Apr 2026
At a glance
- Drugs JNJ-95437446 (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Janssen Research & Development
Most Recent Events
- 24 Dec 2025 Planned End Date changed from 17 Apr 2028 to 24 Apr 2028.
- 05 Dec 2025 Planned End Date changed from 28 Nov 2027 to 17 Apr 2028.
- 13 Aug 2025 New trial record